A phase 1B, open label, dose escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of Axitnib in combination with crizotinib in patients with advanced solid tumors
|Effective start/end date||6/22/15 → 6/30/20|
- PFIZER, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.